Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
The dual primary endpoints were change in KCCQ-CSS (a standard measure of heart failure-related symptoms and physical limitations) and percentage change in body weight from baseline to 52 weeks
In STEP 1, in a population of obese or overweight people without diabetes, those who received semaglutide 2.4 mg plus a lifestyle intervention over 68 weeks lost an average of 14.9% in bodyweight as compared with just a 2.4% reduction in the placebo plus lifestyle intervention group
Komodo Healths platform offers prescription tracking in near real-time, unlocking the capacity to follow healthcare trends as they unfold
CAUTION: Not intended for use by pregnant or nursing women
US$ 24.55
US$ 29.20
US$ 20.90
US$ 28.31
US$ 25.51
